AUM Biosciences advances precision oncology therapeutics to reverse cancer resistance

AUM Biosciences is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. The firm was founded on the premise of enabling a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability, and scalability.

Helmed by industry veterans with successful track records in developing & commercializing innovative cancer therapies, AUM Biosciences’ aims to implement unique approaches towards achieving superior, affordable oncology treatment for cancer patients.

In a conversation with #biztechasia the passionate Chairman & CEO of AUM Biosciences, Vishal Doshi, shared insights into how the organization is developing a pipeline of precision oncology therapeutics, designed to reverse cancer resistance. He also touched on the massive opportunity in the precision oncology space in Asia Pacific and how AUM Biosciences aims to further tap into this industry which is expected to expand into a $274.40 billion market by 2030.

Additionally, Vishal touched on:

The reason for founding AUM Biosciences and how the company aims to make a holistic impact on the healthcare industry, by developing meaningful medicines for patients across the globe
A deep dive into the different drugs, treatments and therapies which AUM Biosciences produces
Navigating through complex jurisdictions and regulations for clinical trials
The pivotal role of collaboration to drive impactful and sustainable change in healthcare
AUM Biosciences merger with Mountain Crest and what’s next for the organization